CommScope's strategic restructuring reduces debt and refocuses on high-growth broadband and enterprise wireless segments. See ...

Invivyd, Inc. advances VYD2311 as a Covid-19 vaccine alternative. Learn about upcoming trials and market opportunities. Click ...

Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today reported financial results for ...

The Company reported a net loss of approximately $4.0 million, or $0.06 per share, for the three months ended September 30, ...

Net Loan-To-Value (LTV) -- 34.5% with a target net LTV range of 20%-25% stated by management. Available Liquidity -- $412 million reported as of quarter-end. Contracted Revenue Backlog -- $3.7 billion ...

This release comes as Writer continues to gain industry adoption and new enterprise-focused customers, including Aptitude ...

The YF-23 and YF-22 were closely matched, and the aircraft may return in another form for the US Navy's F/A-XX.

Strategic process -- Formal engagement with Evercore concluded; current focus is on Phase III clinical execution, with ...

Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) Q3 2025 Earnings Call Transcript November 12, 2025 Atea Pharmaceuticals, Inc.

Meg Alexander appointed Chief Executive Officer effective January 1, 2026; Dr. Jeremy M. Levin to transition to Executive Chair of the Board of DirectorsNext-generation GABA-aminotransferase (GABA-AT) ...

Operator: Greetings, and welcome to the Tenon Medical Third Quarter 2025 Financial Results and Corporate Update Conference ...

Pre-NDA meeting with FDA to discuss brilaroxazine's path to approval for schizophrenia planned in Q4 2025 - - Potential NDA submission for schizophrenia indication targeted for Q2 2026 - - European ...